Scribe Therapeutics Inc.
Scribe Therapeutics Inc. scores highest on Torque (93) and lowest on Price (0). Its PosiPenta is 45.15 out of 100, around the middle of similar companies.
On the Penta Grid this week, Scribe Therapeutics Inc. is Grid #379 of 837 in the Healthcare sector in United States, and Grid #2,402 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Scribe Therapeutics Inc. | 45.15 | 0 | 22 | 51 | 93 | 59 |
| Galectin Therapeutics Inc. | 50.76 | 0 | 33 | 54 | 96 | 71 |
| Enanta Pharmaceuticals, Inc. | 35.04 | 21 | 26 | 54 | 25 | 50 |
| Zura Bio Limited | 52.38 | 30 | 47 | 47 | 68 | 69 |
| Nautilus Biotechnology, Inc. | 46.30 | 29 | 37 | 53 | 49 | 63 |
| Alpha Teknova, Inc. | 50.71 | 11 | 58 | 80 | 48 | 56 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.23 |
| P/B ratio | -2.31 |
EEarnings
| Trailing EPS | ₹-363.71 |
| Forward EPS | ₹-342.55 |
NNitro
| Price | 1901.88 |
| 52-week high | 3750.71 |
| 52-week low | 1278.65 |
| Fall from 52-week high | 49.3% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | -0.29 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹3,600 Cr |
| Insider holding | 18.04% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Scribe Therapeutics Inc.'s PosiPenta score?
Scribe Therapeutics Inc.'s PosiPenta is 45.15 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Scribe Therapeutics Inc. stand on the Penta Grid?
On the Penta Grid this week, Scribe Therapeutics Inc. is Grid #379 of 837 in the Healthcare sector in United States, and Grid #2,402 of 4,000 in United States.
Which PosiPenta pillar is strongest for Scribe Therapeutics Inc.?
Torque (durability), with a score of 93 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Scribe Therapeutics Inc.?
Price (valuation), with a score of 0 out of 100: much weaker than most similar companies.
Has Scribe Therapeutics Inc.'s PosiPenta changed since last week?
Yes, it rose 3.60 points, from 41.55 to 45.15.
PositoAI is for research and education only and is not investment advice.